Coronavirus disease 2019 (COVID-19) in a pregnant women with treatment resistance thrombocytopenic purpura with and suspicion to HELLP syndrome: a case report

Amir Hossein Norooznezhad 1,2, Maryam Nurzadeh 3, Mohammad Hasan Darabi 1 and Mahsa Naemi 2,4*

Abstract

Background: Coronavirus disease 2019 (COVID-19) still is a global emergency. According to the studies, pregnant women are of the at risk populations and any underlying disease(s) might even worsen their condition. The aim of this study is reporting a complex case of immune thrombocytopenic purpura (ITP) during pregnancy who has been diagnosed with COVID-19 as well as suspicion of HELLP syndrome.

Case presentation: A 24-year-old woman with a platelet count of 6000/mL and resistance to conventional therapies was referred. A day after starting 0.5 g/day of methylprednisolone for her, fever and a decrease in SpO2 presented. According to the paraclinical investigations, COVID-19 was diagnosed and the conventional COVID-19 treatments started for her (the methylprednisolone pulse stopped). Due to the increased liver enzymes and low platelet count, with suspicion of HELLP syndrome, cesarean section surgery was performed which resulted in a healthy neonate. Then, the methylprednisolone pulse was restarted for and she developed an increase in the platelet count.

Conclusion: It is not clear how COVID-19 and pregnancy affected the patient’s condition and the underlying disease; however, it seems the delivery and/or restarting the methylprednisolone pulses caused improvement in her condition.

Keywords: COVID-19, Pregnancy, Immune thrombocytopenic purpura, Immunosuppression

Background

Coronavirus disease 2019 (COVID-19) still is a global emergency [1]. So far different systematic reviews and meta-analyses have studied the impact of COVID-19 on pregnant patients [2]. Hematologic consequences of COVID-19 are well documented which some of them such as thrombocytopenia even yielding prognostic values, due to its positive correlation with both disease severity and mortality rate [3, 4]. While the management of immune thrombocytopenic purpura (ITP) in pregnancy is troublesome by itself, thrombocytopenic effects of COVID-19 in a pregnant women with ITP adds more and more to this complexity [5]. Possibly due to lack of evidence, the recommendations derived from the non-pregnant ITP population is applied to pregnant ITP patients with COVID-19, barring some minor precautions. The first-line therapy for these patients is using...
corticosteroids but it is going to be more complicated in the corticosteroids-resistant treatments [6].

Herein, we would like to explain lessons learned from a pregnant case of ITP with suspicion to HELLP (Haemolytic, Elevated Liver Enzymes, and Low Platelet) syndrome. We believe complicated course of this case can make it a worthwhile addition to literature.

**Case presentation**

In April 2020, a 24-year-old primigravida woman at the gestational age of 29 and 1/7 weeks with a history of ITP and splenectomy (11 years ago) was referred to our tertiary level III center. Other than the mentioned condition, she had no underlying disease. The patient was referred from another hospital due to a decreased platelet count (5 mg/day) and intravenous immunoglobulin (IVIG; 1 g/kg). In ours and the previous center, she revealed no signs or symptoms in favor of SARS-CoV-2 infection and claimed no contact with a confirmed/suspected case of COVID-19. At the time of admission, she had no cough, sore throat, dyspnea, chest pain, rhinorhea, myalgia, or gastrointestinal symptoms. There was also no sign of elevated body temperature (37.1 °C), tachypnea (respiratory rate: 14 breaths per min), tachycardia (heart rate: 86 per min), or decreased oxygen saturation (SpO2: 95%). Laboratory investigations showed a normal leukocyte count accompanied by severe thrombocytopenia (6 × 10^3/mL). Moreover, hemoglobin, coagulation profile, lactate dehydrogenase level, and kidney function tests were all normal; however, she had slightly elevated liver enzymes (Table 1). Unfortunately, C-reactive protein was not requested for her upon admission. Due to the lack of response to the previous treatments and after consulting with hematology service (considering her clinical and laboratory status), they decided to start methylprednisolone pulse (0.5 g/day). About 24 h later (after the second pulse), the patient presented fever (38°C) accompanied by SpO2 90% but no other signs or symptoms. Considering this finding and regarding the pandemic, a chest computed tomography (CT) scan (with abdominal shield) was requested immediately which showed bilateral patchy ground-glass opacities and consolidations. Following these findings and after consulting with infectious diseases service, oseltamivir, lopinavir/ritonavir, chloroquine, piperacillin/tazobactam, and azithromycin were started for the patient (methylprednisolone was discontinued after the second pulse) and she was transferred to the COVID-19 ward. Also, the result of reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infection on the day after. Due to the increasing pattern of liver enzymes on hospital day (HD) 9 (Table 1) and with the suspicion of HELLP syndrome, the pulse of methylprednisolone and platelet transfusion started for the patient after a consult with hematology service and she underwent cesarean section without any complication. A healthy male neonate with Apgar scores 9 and 10 was born with negative SARS-CoV-2 RT-PCR result. The pulse continued for the next 4 days and discontinued then (HD13). After 4 treatment-free days, the platelet count was 71,000/mL and no pregnancy- nor ITP-related complications were observed. The follow-ups after 6 months revealed no problem at all with both mother and the infant. This case belongs to a research proposal with the ethical approval code of the Medical

**Table 1** Laboratory findings of the patient before and after treatment with methylprednisolone

| Variable                        | Before MP | HD 1 ‡ | HD 9 †† | HD 13 * | HD 17 ** |
|---------------------------------|-----------|--------|---------|---------|---------|
| White-cell count (per mL)       | 9040      | 10,500 | 9290    | 8200    | 9000    |
| Absolute lymphocyte count (per mL) | 361 (4%)   | 1575 (15%)  | 650 (7%)  | 820 (10%) | 1440 (16%) |
| Absolute neutrophil count (per mL) | 8226 (91%) | 8505 (81%)  | 8268 (89%) | 7134 (87%) | 7470 (83%) |
| Platelet count× 10^3 (per mL)   | 6 × 10^3   | 56     | 6 × 10^3 | 75      | 71      |
| Hemoglobin (gr/dL)              | 11.2      | 11.6   | 10.4    | 9.3     | 11.5    |
| Hematocrit (%)                  | 34        | 35     | 31.3    | 29.3    | 36.4    |
| Erythrocyte sedimentation rate (mm/h) | 57       | N/A    | N/A     | N/A     | N/A     |
| C-reactive protein (mg/L)       | N/A       | 30     | N/A     | N/A     | N/A     |
| Creatinine (mg/dL)              | 0.72      | 0.64   | 0.64    | 0.64    | 0.4     |
| Blood urea nitrogen (mg/dL)     | 9         | 16     | 14      | 26      | 12      |
| Aspartate aminotransferase (U/L) | 53        | N/A    | 346     | 1173    | 133     |
| Alanine aminotransferase (U/L)  | 65        | N/A    | 477     | 2030    | 800     |
| Lactate dehydrogenase (U/L)     | 430       | N/A    | 971     | 1301    | 546     |

*MP* Methylprednisolone pulse, *HD* Hospital day, *N/A* Not applicable

‡ After 1 unit of single donor platelet transfusion.
†† After 10 units of platelet transfusion.
*: The patient was transferred to the COVID-19 ward.
**: Cesarean section performed and MP started.
†: After the last pulse of MP.
‡‡: Four days after last MP pulse.
---: following transfusion. During the hospitalization, other laboratory parameters such as levels of total bilirubin, albumin, fibrinogen, prothrombin time (PT), partial thromboplastin time (PTT), Na, and K were in the normal range.
overlooked. We believe a dramatic response to de-
are normotensive and without proteinuria should not be
diagnosis but atypical cases of HELLP syndrome who
proteinuria will turn the tide in favor of a HELLP syndrome
the platelet count of 13 × 10^3/mL, she received intraven-
gival bleeding at her 24th week of gestation. Considering
a 34-year-old woman previously diagnosed with ITP
patient, but as mentioned before it is highly speculative.
liver makes HELLP syndrome more likely in our pa-
HELLP syndrome as a probable diagnosis. Therefore, pa-
tient underwent an emergency caesarian section on the
HD 9 and received her next five pulses of methylpred-
nisolone. After four treatment-free days, liver enzymes
decreased and platelet count increased.
Gestational thrombocytopenia (mostly with a platelet
count between 130 and 150 × 10^3/mL) might be seen
during pregnancy [7] as the second frequent hematologic-related change of gestation, after anemia
[8]. Very low platelet count and response to corticoste-
roids make this diagnosis very unlikely in our patient
[7]. Thrombocytopenia itself is a complication of
COVID-19 and is a heralding sign of poor prognosis [3].
Papageorghiou et al., concluded that there is a strong as-
association between COVID-19 and preeclampsia [9].
Thus, COVID-19 might have played a significant role in
reducing our patient’s already low platelet counts either
via COVID-19 induced thrombocytopenia or by causing
preeclampsia at its most severe form (i.e., HELLP syndrome).

Differentiation between these two etiologies would be
extremely difficult as both of them can cause elevated
liver enzymes, elevated LDH, elevated BUN/Cr ratio and
of course thrombocytopenia [10]. Hypertension and pro-	einuria will turn the tide in favor of a HELLP syndrome
diagnosis but atypical cases of HELLP syndrome who
are normotensive and without proteinuria should not be
overlooked [11]. We believe a dramatic response to de-
ivery makes HELLP syndrome more likely in our pa-
tient, but as mentioned before it is highly speculative.
Nesr et al. [5], have reported a similar case which was
a 34-year-old woman previously diagnosed with ITP
who presented with dry cough, fever, petechial and gin-
gival bleeding at her 24th week of gestation. Considering
the platelet count of 13 × 10^3/mL, she received intraven-
ous immunoglobulin (1 g/kg) and oral prednisolone (1
mg/ kg) with favorable results. Also, just like our case,
they reported lymphopenia in their patient, too [5].

A dark spot of this report is the synchronism of meth-
ylprednisolone pulse treatment and COVID-19 manifest-
ation (with a short delay). Considering the emerged
median duration of the COVID-19 incubation period
(5.1 days) [12] this question might rise that if the high-
dose Immunosuppressives could decrease this period or
not. We wish that the patient was evaluated for COVID-
19 infection before the methylprednisolone pulse. Also,
early request of erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), and absolute lymphocyte count
could have provided us with some early indicators of
COVID-19 infection. Although as mentioned in the case
presentation, there were no apparent clinical indications
for requesting such tests.

This report presented a pregnant woman with ITP
who developed some features of HELLP syndrome dur-
ing hospitalization which led us to consider emergency
delivery. This report can provide us with invaluable in-
formation on corticosteroid therapy in the treatment of
pregnant women with thrombocytopenia and COVID-19
infection. The physicians should be aware of COVID-19
induced thrombocytopenia and its differential diagnoses,
especially in pregnant patients where finding out the
exact diagnosis will be much more difficult than usual
and if they could not distinguish between etiologies of
thrombocytopenia, it is better to consider the worst-case
scenario in order to prevent any unwanted outcome, just
like our case.

Acknowledgments
The authors are grateful for the kind permission of the patient to use their
medical information in this report.

Authors’ contributions
AhN and MHD contributed in data collection, manuscript drafting and
reviewing, and approval of final manuscript. MNa and MNu has contributed
in case management, data collection, manuscript drafting and reviewing,
and approval of final manuscript. MNa performed the study supervision.

Funding
This study was not funded.

Availability of data and materials
Data would be available at online requests from Dr. Mahsa Naemi, the
responding author.

Declarations
Ethics approval and consent to participate
Authors declare their adhered to the 1975 declaration of Helsinki and its
next revisions. This case belongs to a research proposal with the ethical
approval code of the Medical Ethics Committee of Tehran University of
Medical Sciences (IRB: IR.TUMS.VCR.1398.1082).

Consent for publication
Patient kindly signed a written consent form freely for publishing/using of
her medical data.

Competing interests
Authors declare no actual or potential conflict of interests related to this
study.
Author details
1Medical Biology Research Center, Health Institute Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. 2Maternal, Fetal and Neonatal Research Center, Vali-Asr Hospital, Imam Khomeini Hospital Complexes, Tehran University of Medical Sciences, Tehran, Iran. 3Department of Obstetrics and Gynecology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 4Fetomaternal Department, Shariati Hospital, Tehran University of Medical Sciences, North-Kargar Avenue, Tehran, Iran.

Received: 16 March 2021 Accepted: 2 August 2021

Published online: 18 August 2021

References
1. Norooznezhad AH, Najafi F, Riahi P, Moradinazar M, Shakiba E, Mostafaei S. Primary symptoms, comorbidities, and outcomes of 431 hospitalized patients with confirmative RT-PCR results for COVID-19. Am J Trop Med Hyg. 2020;103(2):834–7.
2. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kow T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320.
3. Terpos E, Ntanasis-Stathopoulos I, Elalany I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834–47.
4. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–8.
5. Nesr G, Garnett C, Bailey C, Arami S. ITP flare with mild COVID-19 infection in pregnancy: a case report. Br J Haematol. 2020. https://doi.org/10.1111/bjh.16928.
6. Rodeghiero F, Cantoni S, Carli G, Carpenedo M, Carral V, Chiurazzi F, et al. Practical recommendations for the management of patients with ITP during the COVID-19 pandemic. Mediterr J Hematol Infect Dis. 2021;13(1):e2021032.
7. Ciobanu AM, Colibaba S, Cimpoca B, Peltecu G, Panatescu AM. Thrombocytopenia in pregnancy. Maedica. 2016;11(1):55–60.
8. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121(1):38–47.
9. Papageorghiou AT, Deruelle P, Gunier RB, Rauch S, Garcia-May PK, Mhatre M, et al. Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study. Am J Obstet Gynecol. 2021. https://doi.org/10.1016/j.ajog.2021.05.014.
10. Futterman I, Toaff M, Navi L, Clare CA. COVID-19 and HELLP: overlapping clinical pictures in two gravid patients. Am J Perinatol Rep. 2020;10(02):e179–e82.
11. Ronnye L, Länsberg J-K, Vikhareva O, Hansson SR, Herbst A, Zaigham M. Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery. BMC Pregnancy Childbirth. 2020;20(1):1–8.
12. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions